For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...

“This is an invaluable study population,” he said. “Continuing to follow them on treatment may provide the best test of the amyloid hypothesis that the field can undertake and stands to ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

But a new study looking at the anti-amyloid drug gantenerumab could change all that. Published in the Lancet Neurology ...

Jake Heinrichs prepares for his infusion treatment with an experimental anti-amyloid Alzheimer's drug while at home in New York, on Wednesday, March 12, 2025. Credit: AP/Heather Khalifa The new ...

Louis. The findings suggest – for the first time in a clinical trial – that early treatment to remove amyloid plaques from the brain many years before symptoms arise can delay the onset of ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...